Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluorocyclopentenylcytosine - Rexahn Pharmaceuticals

Drug Profile

Fluorocyclopentenylcytosine - Rexahn Pharmaceuticals

Alternative Names: FCPEC; RX 3117

Latest Information Update: 09 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Antineoplastics; Nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bladder cancer; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 07 Aug 2019 Updated efficacy data from a phase IIa trial in Pancreatic cancer released by Rexahn Pharmaceuticals
  • 16 Apr 2019 Rexahn enters into a collaboration and licence agreement for fluorocyclopentenylcytosine for Pancreatic cancer and other Cancers in Greater China
  • 16 Apr 2019 BioSense Global plans a phase II trial for Cancer in Greater China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top